Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo

Ribo will receive $60 million upfront, with potential milestone payments reaching $4.4 billion, plus royalties on future sales.
In this photo illustration, Madrigal Pharmaceuticals logo is seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)
In this photo illustration, Madrigal Pharmaceuticals logo is seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)
Profile Image
Arnab Paul·Stocktwits
Published Feb 11, 2026   |   5:38 AM EST
Share
·
Add us onAdd us on Google

Madrigal Pharmaceuticals (MDGL), on Wednesday, announced an exclusive global licensing agreement with Suzhou Ribo Life Science and its unit Ribocure Pharmaceuticals for six preclinical small interfering RNA (siRNA) programs targeting metabolic dysfunction-associated steatohepatitis (MASH).

Ribo has granted Madrigal an exclusive global license to develop, manufacture, and commercialize the six compounds. Under the deal, Ribo will receive $60 million upfront, with potential milestone payments reaching $4.4 billion, plus royalties on future sales.

siRNA technology works by muting genes responsible for disease-driving proteins. Madrigal plans to combine the technology with its drug Rezdiffra. The company’s pipeline also includes MGL-2086 with human studies scheduled later this year.

MDGL shares closed around 2% lower on Tuesday.

Read updates to this developing story on Stocktwits.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share
·
Add us onAdd us on Google
Read about our editorial guidelines and ethics policy